Provention Bio, Inc. (NASDAQ:PRVB – Get Rating) – Equities researchers at Cantor Fitzgerald increased their FY2023 earnings per share estimates for shares of Provention Bio in a research report issued on Monday, November 21st. Cantor Fitzgerald analyst P. Agrawal now anticipates that the company will post earnings per share of ($1.83) for the year, up from their prior estimate of ($1.95). The consensus estimate for Provention Bio’s current full-year earnings is ($1.62) per share.
PRVB has been the subject of a number of other research reports. SVB Leerink raised their price objective on Provention Bio from $16.00 to $19.00 and gave the stock an “outperform” rating in a research report on Monday. Oppenheimer raised their target price on Provention Bio from $14.00 to $18.00 and gave the stock an “outperform” rating in a research report on Friday, November 18th. Jefferies Financial Group raised their target price on Provention Bio from $18.00 to $22.00 and gave the stock a “buy” rating in a research report on Friday, November 18th. Finally, Chardan Capital raised their target price on Provention Bio from $24.00 to $30.00 and gave the stock a “buy” rating in a research report on Friday, November 18th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $21.40.
Provention Bio Price Performance
Institutional Investors Weigh In On Provention Bio
Hedge funds and other institutional investors have recently bought and sold shares of the business. Bioimpact Capital LLC acquired a new stake in Provention Bio during the 2nd quarter valued at $2,370,000. Nisa Investment Advisors LLC acquired a new stake in Provention Bio during the 1st quarter valued at $332,000. Rice Hall James & Associates LLC increased its holdings in Provention Bio by 2.6% during the 2nd quarter. Rice Hall James & Associates LLC now owns 225,785 shares of the company’s stock valued at $903,000 after purchasing an additional 5,720 shares in the last quarter. Amalgamated Bank acquired a new stake in Provention Bio during the 1st quarter valued at $49,000. Finally, Sigma Planning Corp increased its holdings in Provention Bio by 22.3% during the 2nd quarter. Sigma Planning Corp now owns 153,690 shares of the company’s stock valued at $615,000 after purchasing an additional 28,070 shares in the last quarter. 37.39% of the stock is owned by institutional investors and hedge funds.
About Provention Bio
Provention Bio, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-3279, which has completed Phase Ib clinical trial for the treatment of lupus; PRV-101, a coxsackie virus B (CVB) vaccine for the prevention of acute CVB infections and onset of T1D; and PRV-015, which is in phase IIb clinical trial for the treatment of gluten-free diet non-responding celiac disease.
- Get a free copy of the StockNews.com research report on Provention Bio (PRVB)
- Is the 60/40 Portfolio Mix Still in Vogue?
- Institutional Support for Analog Devices Remains High
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
- Microsoft Shares: Is it Time to Back Up the Truck?
- Three CBD Stocks to Dominate a Budding Industry
Receive News & Ratings for Provention Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Provention Bio and related companies with MarketBeat.com's FREE daily email newsletter.